参考资料 1.https://www.aacrmeetingnews.org/news/aacr-ceo-margaret-foti-phd-md-hc-invites-you-to-the-115th-annual-meeting-of-the-american-association-for-cancer-research/ 2.https://www.aacrmeetingnews.org/news/data-science-artificial-intel...
The annual American Association for Cancer Research (AACR) meeting provides a platform for scientists, clinicians and other stakeholders to share the latest advances in cancer science and medicine. Here, we outline some highlights of the 2024 meeting....
The 115th American Association for Cancer Research (AACR) Annual Meeting was held in San Diego, USA, April 5-10, 2024. The AACR Annual Meeting, as one of the leading cancer conferences in the world, has always been a focus of attention in the global pharmaceutical industry. The themeof t...
1.https://www.aacrmeetingnews.org/news/aacr-ceo-margaret-foti-phd-md-hc-invites-you-to-the-115th-annual-meeting-of-the-american-association-for-cancer-research/ 2.https://www.aacrmeetingnews.org/news/data-science-artificial-intelligence-and-technology-among-hot-topics-within-program/ 3.https:...
您的需求可更快得以响应。咨询电话：021-50896659咨询邮箱：marketing@genoway-sh.com官方网站：www.genoway.com参考：https://www.aacr.org/meeting/aacr-annual-meeting-2024/版权声明：本文版权归上海基锘威生物所有，如需转载请标明出处。部分图片来源于网络，如有侵权请后台留言 ...
咨询电话:021-50896659 咨询邮箱:marketing@genoway-sh.com 官方网站:www.genoway.com 参考: https://www.aacr.org/meeting/aacr-annual-meeting-2024/ 声明:本文版权归上海基锘威生物所有,如需转载请标明出处。部分图片来源于网络,如有侵权请后台...
同宜医药今日宣布,公司新一代Bi-XDC偶联药物C-PROTAC的研究进展入选2024年美国癌症研究协会年会(AACR Annual Meeting 2024),该研究摘要将被收录于AACR的在线论文集中。这一重要突破意味着同宜医药新一代Bi-XDC偶联药物C-PROTAC将在国际学术会议舞台上正式亮相,向国内外专家展示其在癌症治疗领域的巨大潜力。本届AACR...
2024年美国癌症研究协会年会 (AACR ANNUAL MEETING 2024)于当地时间4月5日-10日在美国圣地亚哥召开。在本次会议上,映恩生物以壁报形式公布基于其自主研发的抗肿瘤ADC平台DITAC (Duality Immune Toxin Antibody Conjugate)开发的DB-1310、DB-1311创新项目的研究成果,信息如下: 壁报信息1 Title: A Phase 1/2a, multic...
JAB-30355正在美国进行I/IIa期临床试验,以评估JAB-30355对晚期实体瘤患者的安全性和有效性。 AACR 2024年会将于2024年4月5日至4月10日在美国加利福尼亚州圣迭戈市举行。更多信息请访问AACR大会官网:https://www.aacr.org/meeting/aacr-annual-meeting-2024...
Details of the results presented at 2024 AACR Annual Meeting are as follows: Title Exploratory biomarker analysis of phase 3 ASTRUM-005 study: Serplulimab versus placebo plus chemotherapy for extensive-stage small cell lung cancer Methods